The expanded authorization was based on data from the phase 2/3 BLAZE-1 trial. The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab plus ...
Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have ...
Researchers say identified mAbs could represent “a basis to develop a treatment that is urgently needed as measles virus ...
We read with great interest the recent article by Tsai et al,1 which compared characteristics between primary neuromyelitis ...
Scientists at La Jolla Institute for Immunology (LJI) are the first in the world to characterize human antibodies capable of ...
Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have ...
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...
Crohn's disease and ulcerative colitis are complex diseases that have required the use of multiple modalities to aid in treatment. With an increasing understanding of the underlying pathogenetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results